Avertix Medical, Inc. (“Avertix” or the “Company”), a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, and BIOS Acquisition Corporation (dba BioPlus Acquisition Corp.) (“BIOS”) (Nasdaq: BIOS), a special purpose acquisition company, announced that the companies have entered into a definitive merger agreement for a business combination (the “Transaction”) that would result in Avertix becoming a publicly traded company on Nasdaq. The combined company, which will be named Avertix Medical, Inc., will have an enterprise value of approximately $195 million. Avertix is a medical technology company commercializing an implantable device for cardiovascular disease management.
Read the full article: Avertix to Become Publicly Traded via Merger with BIOS Acquisition Corporation //
Source: https://www.globenewswire.com/news-release/2023/05/03/2660360/0/en/Avertix-Maker-of-First-and-Only-FDA-Approved-Implantable-Heart-Attack-Warning-System-to-Become-Publicly-Traded-via-Merger-with-BIOS-Acquisition-Corporation.html